de la Cruz-Merino Luis, Lejeune Marylène, Nogales Fernández Esteban, Henao Carrasco Fernando, Grueso López Ana, Illescas Vacas Ana, Pulla Mariano Provencio, Callau Cristina, Álvaro Tomás
Clinical Oncology Department, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain.
Clin Dev Immunol. 2012;2012:756353. doi: 10.1155/2012/756353. Epub 2012 Aug 15.
Hodgkin's lymphoma represents one of the most frequent lymphoproliferative syndromes, especially in young population. Although HL is considered one of the most curable tumors, a sizeable fraction of patients recur after successful upfront treatment or, less commonly, are primarily resistant. This work tries to summarize the data on clinical, histological, pathological, and biological factors in HL, with special emphasis on the improvement of prognosis and their impact on therapeutical strategies. The recent advances in our understanding of HL biology and immunology show that infiltrated immune cells and cytokines in the tumoral microenvironment may play different functions that seem tightly related with clinical outcomes. Strategies aimed at interfering with the crosstalk between tumoral Reed-Sternberg cells and their cellular partners have been taken into account in the development of new immunotherapies that target different cell components of HL microenvironment. This new knowledge will probably translate into a change in the antineoplastic treatments in HL in the next future and hopefully will increase the curability rates of this disease.
霍奇金淋巴瘤是最常见的淋巴增殖性综合征之一，尤其在年轻人群中。尽管霍奇金淋巴瘤被认为是最可治愈的肿瘤之一，但相当一部分患者在初始治疗成功后会复发，或者较少见地，一开始就耐药。这项工作试图总结霍奇金淋巴瘤在临床、组织学、病理学和生物学方面的数据，特别强调预后的改善及其对治疗策略的影响。我们对霍奇金淋巴瘤生物学和免疫学认识的最新进展表明，肿瘤微环境中浸润的免疫细胞和细胞因子可能发挥不同功能，这些功能似乎与临床结果密切相关。在开发针对霍奇金淋巴瘤微环境不同细胞成分的新免疫疗法时，已经考虑了旨在干扰肿瘤里德-斯腾伯格细胞与其细胞伙伴之间相互作用的策略。这一新知识可能会在不久的将来改变霍奇金淋巴瘤的抗肿瘤治疗方式，并有望提高这种疾病的治愈率。
